"The U.S. Food and Drug Administration approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program "...
The expected manifestations of PROCRIT® (epoetin alfa) overdosage include signs and symptoms associated with an excessive and/or rapid increase in hemoglobin concentration, including any of the cardiovascular events described in WARNINGS and listed in ADVERSE REACTIONS. Patients receiving an overdosage of PROCRIT® (epoetin alfa) should be monitored closely for cardiovascular events and hematologic abnormalities. Polycythemia should be managed acutely with phlebotomy, as clinically indicated. Following resolution of the effects due to PROCRIT® (epoetin alfa) overdosage, reintroduction of PROCRIT® (epoetin alfa) therapy should be accompanied by close monitoring for evidence of rapid increases in hemoglobin concentration ( > 1 gm/dL per 14 days). In patients with an excessive hematopoietic response, reduce the PROCRIT® (epoetin alfa) dose in accordance with the recommendations described in DOSAGE AND ADMINISTRATION.
PROCRIT® (epoetin alfa) is contraindicated in patients with:
- Uncontrolled hypertension.
- Known hypersensitivity to mammalian cell-derived products.
- Known hypersensitivity to Albumin (Human).
Last reviewed on RxList: 6/20/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Procrit Information
Procrit - User Reviews
Procrit User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.